COVID-19 Treatments for Health Professionals

Antiviral Medicines

Paxlovid and Molnupiravir are two oral antiviral medications approved with emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) that can help treat COVID-19. OU Health has these available at Oklahoma Children's Hospital Pharmacy. Prescriptions can be written or sent electronically. Call (405) 271-2156 or fax to (405) 271-2158. For updates on how many courses of these medications are available at different sites, you can check COVID-19 Therapeutics Locator.

Paxlovid (nirmatrelvir and ritonavir)

Paxlovid is an oral antiviral medication used to treat mild-to-moderate COVID-19 in adults and children. Children must be 12 years of age and older, weighing at least 88 pounds. The FDA recently authorized the emergency use of PAXLOVID in patients with a positive COVID-19 test, and who are at high risk of progression to severe COVID-19. Paxlovid is authorized only for outpatient treatment of COVID-19 and should not be used longer than 5 consecutive days. It must be started within 5 days of the onset of symptoms. Paxlovid has many important drug-drug interactions which must be reviewed. Here is an online tool to help check for these drug interactions.

• Patient Paxlovid Fact Sheet (PDF)
• Provider Paxlovid Fact Sheet (PDF)

Molnupiravir

Molnupiravir is an oral antiviral medication with emergency use authorization (EUA) for outpatient treatment of mild-to-moderate COVID-19 in patients. Patients must be 18 years of age and older and are at risk for progression to severe disease. Due to decreased efficacy and teratogenicity, it is recommended third line for outpatient therapy. Molnupiravir is authorized only for outpatient treatment of COVID-19 and should not be used longer than five consecutive days.

• Patient Molnupiravir Fact Sheet (PDF)
• Provider Molnupiravir Fact Sheet (PDF)

Remdesivir

Remdesivir is an injectable antiviral that is available at the OU Health Edmond Medical Center COVID infusion clinic. It is now FDA approved for outpatient use to treat mild to moderate COVID-19 in patients at high risk for progression to severe COVID-19. It is infused daily for 3 days. Remdesivir is especially useful for patients who are unable to receive Paxlovid.

• Remdesivir Order Form (PDF)

If you are an OU Health Provider and would like to order Remdesivir for a patient, please fill out this form and fax to the number on the form, or email to OUMC.COVID.MAB.Approval@ouhealth.com.

Monoclonal Antibody Treatment

Due to the changing COVID-19 variants that are resistant to monoclonal antibody treatment, OU Health is not offering any monoclonal antibody treatment as this time.

If you are a patient looking for information on COVID-19 services and treatment, please visit this page.